San Francisco-based biotech firm NewLimit, co-founded by Coinbase CEO Brian Armstrong, has recently raised $130 million in Series B funding. This significant investment aims to accelerate the company's mission to extend human healthspan through advanced epigenetic reprogramming. The funding round was led by Kleiner Perkins, with participation from new investors including Khosla Ventures, Human Capital, Valor Equity Partners, Nat Friedman, and Daniel Gross.
NewLimit focuses on developing medicines that restore youthful function to old cells by reprogramming the epigenome. The company leverages cutting-edge technologies such as single-cell multi-omics, machine learning, and high-throughput functional assays to identify epigenetic features of aging and discover rejuvenating interventions. Their approach targets the biological mechanisms of aging, aiming to increase the number of healthy years in human life.
Earlier this year, in March 2025, NewLimit announced a significant breakthrough in its research. Scientists at the company identified new transcription factor sets capable of restoring youthful functionality to both hepatocytes (liver cells) and T cells, a critical component of the immune system. This discovery underscores the potential of epigenetic reprogramming to reverse cellular aging and improve organ function.
The company's financial backing now totals over $150 million, including an initial $110 million founding investment and a $40 million Series A round. This substantial capitalization positions NewLimit as a prominent player in the rapidly expanding longevity biotech sector. Brian Armstrong, in a recent social media post, highlighted the company's work, stating, "Great overview of the work @newlimit is doing to extend human longevity."
NewLimit operates within a competitive landscape that includes other well-funded longevity startups like Altos Labs and Retro Biosciences, all striving to make fundamental advancements in human healthspan. The company's long-term ambition is to significantly extend human healthspan, focusing on quality of life rather than merely lifespan extension. Armstrong also recommended subscribing to the "@corememory on YouTube as well," a channel that explores technology, science, and future advancements, including biotechnology.